冠状动脉动脉瘤的病理生理学,诊断和管理:一篇综述
Rengin Çetin Güvenç1, Abdullah Ayar Al Arfaj1, Hola Razouk1
1Department of Cardiology, Okan University School of Medicine, 34959 Istanbul, Turkey.
Reviews in cardiovascular medicine
|September 10, 2025
概括
冠状动脉动脉瘤 (CAA) 是心脏成像中的常见发现. 本综述涵盖CAA的原因,血栓形成和破裂等风险,以及从医疗治疗到手术干预的管理选择.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 血管外科 血管外科
背景情况:
- 冠状动脉动脉瘤 (CAA) 在接受冠状动脉成像的患者中被发现多达8%.
- 动脉样硬化诱导的积极重塑是主要原因,尽管先天性,炎症性和创伤性因素也会有所贡献.
- CAA带来风险,包括血栓形成和远端栓塞,破裂是一种罕见但严重的并发症.
研究的目的:
- 为提供冠状动脉动脉瘤的全面概述.
- 详细说明命名,分类,病理生理学和诊断方法.
- 强调当前和新兴的治疗策略来管理CAA相关的风险.
主要方法:
- 关于冠状动脉动脉瘤的现有文献的综述.
- 综合有关病因,临床表现和并发症的数据.
- 分析当前的管理模式,包括医疗,皮肤间和外科手术.
主要成果:
- CAA经常与动脉样硬化的疾病有关.
- 血栓形成和栓塞是严重的并发症.
- 管理策略是根据动脉瘤特征和患者风险因素量身定制的.
结论:
- 冠状动脉动脉瘤需要仔细评估和管理.
- 穿皮排除适用于具有破裂或血栓形成风险的动脉瘤.
- 手术纠正只适用于复杂的病例,或者当皮肤穿透的选择不适合时.
更多相关视频
相关概念视频
Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Aneurysm III: Interprofessional Care
257
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
257
Angina IV: Management
241
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
241
Aneurysm II: Clinical Manifestations and Diagnostic Studies
308
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
308
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Aortic Regurgitation III: Medical Management
401
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
401


